These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26343106)

  • 1. Prevalence of neutralizing antibodies against liver-tropic adeno-associated virus serotype vectors in 100 healthy Chinese and its potential relation to body constitutions.
    Ling C; Wang Y; Feng YL; Zhang YN; Li J; Hu XR; Wang LN; Zhong MF; Zhai XF; Zolotukhin I; Srivastava A; Ling CQ
    J Integr Med; 2015 Sep; 13(5):341-6. PubMed ID: 26343106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors.
    Liu Q; Huang W; Zhang H; Wang Y; Zhao J; Song A; Xie H; Zhao C; Gao D; Wang Y
    Gene Ther; 2014 Aug; 21(8):732-8. PubMed ID: 24849042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia.
    Li C; Narkbunnam N; Samulski RJ; Asokan A; Hu G; Jacobson LJ; Manco-Johnson MJ; Monahan PE;
    Gene Ther; 2012 Mar; 19(3):288-94. PubMed ID: 21697954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing Antibodies Against Adeno-Associated Viral Capsids in Patients with mut Methylmalonic Acidemia.
    Harrington EA; Sloan JL; Manoli I; Chandler RJ; Schneider M; McGuire PJ; Calcedo R; Wilson JM; Venditti CP
    Hum Gene Ther; 2016 May; 27(5):345-53. PubMed ID: 26790480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients.
    Leborgne C; Latournerie V; Boutin S; Desgue D; Quéré A; Pignot E; Collaud F; Charles S; Simon Sola M; Masat E; Jouen F; Boyer O; Masurier C; Mingozzi F; Veron P
    Cell Immunol; 2019 Aug; 342():103780. PubMed ID: 29571923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroprevalence of binding and neutralizing antibodies against 18 adeno-associated virus types in patients with neuromuscular disorders.
    Wang X; Klann PJ; Wiedtke E; Sano Y; Fischer N; Schiller L; Elfert A; Güttsches AK; Weyen U; Grimm D; Vorgerd M; Bayer W
    Front Immunol; 2024; 15():1450858. PubMed ID: 39399494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques.
    Greig JA; Calcedo R; Grant RL; Peng H; Medina-Jaszek CA; Ahonkhai O; Qin Q; Roy S; Tretiakova AP; Wilson JM
    Vaccine; 2016 Dec; 34(50):6323-6329. PubMed ID: 27817961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals.
    Mimuro J; Mizukami H; Shima M; Matsushita T; Taki M; Muto S; Higasa S; Sakai M; Ohmori T; Madoiwa S; Ozawa K; Sakata Y
    J Med Virol; 2014 Nov; 86(11):1990-7. PubMed ID: 24136735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome.
    Aronson SJ; Veron P; Collaud F; Hubert A; Delahais V; Honnet G; de Knegt RJ; Junge N; Baumann U; Di Giorgio A; D'Antiga L; Ginocchio VM; Brunetti-Pierri N; Labrune P; Beuers U; Bosma PJ; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1297-1305. PubMed ID: 31502485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort.
    Perocheau DP; Cunningham S; Lee J; Antinao Diaz J; Waddington SN; Gilmour K; Eaglestone S; Lisowski L; Thrasher AJ; Alexander IE; Gissen P; Baruteau J
    Hum Gene Ther; 2019 Jan; 30(1):79-87. PubMed ID: 30027761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence of neutralizing antibodies against AAV serotype 1 in healthy subjects in China: implications for gene therapy and vaccines using AAV1 vector.
    Liu Q; Huang W; Zhao C; Zhang L; Meng S; Gao D; Wang Y
    J Med Virol; 2013 Sep; 85(9):1550-6. PubMed ID: 23852678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies.
    Lotfinia M; Abdollahpour-Alitappeh M; Hatami B; Zali MR; Karimipoor M
    Clin Exp Med; 2019 Aug; 19(3):289-298. PubMed ID: 31054018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats.
    Li P; Boenzli E; Hofmann-Lehmann R; Helfer-Hungerbuehler AK
    PLoS One; 2019; 14(3):e0212811. PubMed ID: 30897117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered adeno-associated virus 3 vector with reduced reactivity to serum antibodies.
    Ito M; Takino N; Nomura T; Kan A; Muramatsu SI
    Sci Rep; 2021 Apr; 11(1):9322. PubMed ID: 33927271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adeno-associated virus antibody profiles in newborns, children, and adolescents.
    Calcedo R; Morizono H; Wang L; McCarter R; He J; Jones D; Batshaw ML; Wilson JM
    Clin Vaccine Immunol; 2011 Sep; 18(9):1586-8. PubMed ID: 21775517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive
    Kruzik A; Koppensteiner H; Fetahagic D; Hartlieb B; Dorn S; Romeder-Finger S; Coulibaly S; Weber A; Hoellriegl W; Horling FM; Scheiflinger F; Reipert BM; de la Rosa M
    Hum Gene Ther Methods; 2019 Apr; 30(2):35-43. PubMed ID: 30734588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter assessment and longitudinal study of the prevalence of antibodies and related adaptive immune responses to AAV in adult males with hemophilia.
    Pabinger I; Ayash-Rashkovsky M; Escobar M; Konkle BA; Mingot-Castellano ME; Mullins ES; Negrier C; Pan L; Rajavel K; Yan B; Chapin J
    Gene Ther; 2024 May; 31(5-6):273-284. PubMed ID: 38355967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeated delivery of adeno-associated virus vectors to the rabbit airway.
    Beck SE; Jones LA; Chesnut K; Walsh SM; Reynolds TC; Carter BJ; Askin FB; Flotte TR; Guggino WB
    J Virol; 1999 Nov; 73(11):9446-55. PubMed ID: 10516053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seroprevalence of Adeno-Associated Virus Neutralizing Antibodies in Males with Duchenne Muscular Dystrophy.
    Verma S; Nwosu SN; Razdan R; Upadhyayula SR; Phan HC; Koroma AA; Leguizamo I; Correa NS; Kuipa M; Lee D; Vanderford TH; Gardner MR
    Hum Gene Ther; 2023 May; 34(9-10):430-438. PubMed ID: 36324212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for Neutralizing Antibodies Against Natural and Engineered AAV Capsids in Nonhuman Primate Retinas.
    Day TP; Byrne LC; Flannery JG; Schaffer DV
    Methods Mol Biol; 2018; 1715():239-249. PubMed ID: 29188518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.